EQS-Adhoc: CompuGroup Medical SE & Co. KGaA: CVC announces a voluntary public tender offer based on an investment agreement concluded with CompuGroup Medical SE & Co. KGaA
EQS-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Tender Offer Today, CompuGroup Medical SE & Co. KGaA (CGM or the Company), together with its general partner, CompuGroup Medical Management SE, its majority shareholder GT 1 Vermögensverwaltung GmbH (the Majority Shareholder), Kronen 2944 GmbH (to be renamed GT2 Beteiligungen und Software GmbH, GT2) as well as SCUR-Alpha 269 GmbH (to be renamed Caesar BidCo GmbH, the Bidder) and SCUR-Alpha 1776 GmbH (to be renamed Caesar HoldCo GmbH), both controlled by CVC Capital Partners plc (CVC), entered into an investment agreement on the terms and conditions of a strategic partnership with the Bidder (the Investment Agreement).
In accordance with the Investment Agreement, the Bidder today announces its intention to submit a voluntary public tender offer to the shareholders of CGM at an offer price of EUR 22.00 per share in cash (the Offer). This corresponds to a premium of approximately 51% over the volume-weighted average price of CGM-shares over the past three months. The Offer will stipulate a minimum acceptance threshold of 17% and will be subject, in particular, to merger control and other regulatory clearances. In the Investment Agreement, CGM’s general partner and supervisory board have agreed in principle to support the Bidder’s intention to pursue a potential delisting of CGM immediately after completion of the Offer. Furthermore, the parties of the Investment Agreement have agreed to pursue a more efficient capital structure. To this end, various banks have undertaken to provide credit facilities in the event of the takeover being completed. The Majority Shareholder, Mr Frank Gotthardt and GT2 are to be regarded as related parties of CGM within the meaning of section 111a (1) sentence 2 AktG. The Majority Shareholder currently holds approximately 26.54% of the shares in the Company and all shares in GT2, while Mr Frank Gotthardt, the majority shareholder of the Majority Shareholder, holds 6.83% of the shares in the Company. The Majority Shareholder and Mr Frank Gotthardt are attributed the majority of the voting rights in CGM. At the same time, the Majority Shareholder is the sole shareholder of the general partner of CGM. Furthermore, the Majority Shareholder and the Bidder have today entered into a shareholders’ agreement (the Shareholders’ Agreement). According to this agreement, the shareholder group around the Gotthardt Family will enter into a strategic partnership with the Bidder, subject to the completion of the Offer. Consequently, the members of the shareholder group around the Gotthardt Family will remain invested in the Company to the same extent as before. The parties have agreed not to enter into a domination and/or profit and loss transfer agreement for a period of two years following closing of the offer. The general partner and the Supervisory Board of the Company welcome the Offer and will carefully review the Offer document after its publication and issue a reasoned statement in accordance with Section 27 WpÜG. Subject to such review, they currently expect to recommend to the shareholders of CGM to accept the Offer. In addition to other corporate bodies of the Company and the general partner, the supervisory board of CGM has approved the conclusion of the Investment Agreement. End of Inside Information
09-Dec-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | CompuGroup Medical SE & Co. KGaA |
Maria Trost 21 | |
56070 Koblenz | |
Germany | |
Phone: | +49 (0)160 3630362 |
Fax: | +49 (0)261 8000 3200 |
E-mail: | investor@cgm.com |
Internet: | www.cgm.com |
ISIN: | DE000A288904 |
WKN: | A28890 |
Indices: | SDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2046429 |
End of Announcement | EQS News Service |
|
2046429 09-Dec-2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
The most important financial data at a glance | ||||||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
Sales1 | 717,02 | 745,81 | 837,26 | 1.025,32 | 1.129,74 | 1.187,66 | 1.165,00 | |
EBITDA1,2 | 187,84 | 178,13 | 197,48 | 213,39 | 216,35 | 229,76 | 235,00 | |
EBITDA-Margin3 | 26,20 | 23,88 | 23,59 | 20,81 | 19,15 | 19,35 | 20,17 | |
EBIT1,4 | 143,23 | 115,27 | 121,77 | 102,68 | 104,03 | 98,00 | 0,00 | |
EBIT-Margin5 | 19,98 | 15,46 | 14,54 | 10,01 | 9,21 | 8,25 | 0,00 | |
Net Profit (Loss)1 | 96,34 | 66,15 | 73,42 | 69,03 | 74,12 | 46,87 | 0,00 | |
Net-Margin6 | 13,44 | 8,87 | 8,77 | 6,73 | 6,56 | 3,95 | 0,00 | |
Cashflow1,7 | 136,35 | 110,50 | 149,93 | 165,27 | 145,03 | 179,53 | 0,00 | |
Earnings per share8 | 1,92 | 1,33 | 1,40 | 1,30 | 1,40 | 0,88 | 0,89 | |
Dividend per share8 | 0,50 | 0,50 | 0,50 | 0,50 | 0,50 | 1,00 | 0,50 |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
INVESTOR-INFORMATION | ||||||
©boersengefluester.de | ||||||
CompuGroup Medical | ||||||
WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
A28890 | DE000A288904 | SE & Co. KGaA | 1.168,19 Mio € | 04.05.2007 | Halten | 9F299HQG+3H |
PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
18,58 | 35,62 | 0,52 | 18,66 | 2,01 | 6,51 | 0,98 |
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
0,50 | 1,00 | 0,50 | 2,30% |
Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
14.05.2025 | 30.04.2025 | 31.07.2025 | 07.11.2024 | 06.03.2025 |
Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
+39,48% | +7,68% | -42,64% | -41,37% | +20,78% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.